AKR1C3 is a biomarker and druggable target for oropharyngeal tumors

被引:0
作者
Caterina Peraldo-Neia
Paola Ostano
Maurizia Mello-Grand
Francesca Guana
Ilaria Gregnanin
Donatella Boschi
Simonetta Oliaro-Bosso
Agnese Chiara Pippione
Andrea Carenzo
Loris De Cecco
Stefano Cavalieri
Arianna Micali
Federica Perrone
Gianluca Averono
Paolo Bagnasacco
Riccardo Dosdegani
Laura Masini
Marco Krengli
Paolo Aluffi-Valletti
Guido Valente
Giovanna Chiorino
机构
[1] Fondazione Edo ed Elvo Tempia,Laboratory of Cancer Genomics
[2] University of Turin,Department of Drug Science and Technology
[3] Fondazione IRCCS Istituto Nazionale dei Tumori,Integrated Biology Platform, Department of Applied Research and Technology Development
[4] Fondazione IRCCS Istituto Nazionale dei Tumori,Head and Neck Medical Oncology Unit
[5] Fondazione IRCCS Istituto Nazionale dei Tumori,Department of Pathology and Laboratory Medicine
[6] Otorhinolaryngology Unit,Department of Translational Medicine
[7] Ospedale degli Infermi,undefined
[8] Otorhinolaryngology Unit,undefined
[9] Ospedale Sant’Andrea,undefined
[10] UPO School of Medicine,undefined
[11] Radiotherapy Unit,undefined
[12] Department of Health Sciences,undefined
[13] UPO School of Medicine,undefined
[14] Otorhinolaryngology Unit,undefined
来源
Cellular Oncology | 2021年 / 44卷
关键词
Oropharynx cancer; HPV status; Prognosis; AKR1C3; Biomarker; Target therapy; Cisplatin;
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:357 / 372
页数:15
相关论文
共 559 条
[1]  
Pai SI(2012)HPV-associated head and neck cancers Otolaryngol. Clin. N. Am. 45 xi-xii
[2]  
Siegel RL(2019)Cancer statistics CA Cancer J. Clin. 69 7-34
[3]  
Miller KD(2017)Evidence-based treatment options in recurrent and/or metastatic squamous cell carcinoma of the head and neck Front. Oncol. 7 72-7356
[4]  
Jemal A(2002)Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma Cancer Res. 62 7350-46
[5]  
Argiris A(2012)Current treatment options for metastatic head and neck cancer Curr. Treat. Options in Oncol. 13 35-1630
[6]  
Harrington KJ(2017)Differential resistance to platinum-based drugs and 5-fluorouracil in p22phox-overexpressing oral squamous cell carcinoma: Implications of alternative treatment strategies Head Neck 39 1621-1115
[7]  
Tahara M(2017)Nivolumab versus standard, single-agent therapy of investigator's choice in recurrent or metastatic squamous cell carcinoma of the head and neck (CheckMate 141): health-related quality-of-life results from a randomised, phase 3 trial Lancet Oncol. 18 1104-1867
[8]  
Schulten J(2016)Nivolumab for recurrent squamous-cell carcinoma of the head and neck N. Engl. J. Med. 375 1856-72
[9]  
Chomette P(2010)Cancer of the oral cavity and oropharynx Cancer Imaging 10 62-350
[10]  
Ferreira Castro A(2009)Lifestyle risk factors for oral cancer Oral Oncol. 45 340-300